AR052054A1 - Procesos para la preparacion de derivados del acido 3-fenil-2-arilalquilpropionico - Google Patents
Procesos para la preparacion de derivados del acido 3-fenil-2-arilalquilpropionicoInfo
- Publication number
- AR052054A1 AR052054A1 ARP050105310A ARP050105310A AR052054A1 AR 052054 A1 AR052054 A1 AR 052054A1 AR P050105310 A ARP050105310 A AR P050105310A AR P050105310 A ARP050105310 A AR P050105310A AR 052054 A1 AR052054 A1 AR 052054A1
- Authority
- AR
- Argentina
- Prior art keywords
- processes
- preparation
- arilalquilpropionico
- fenil
- acid derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P11/00—Preparation of sulfur-containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/52—Propionic acid; Butyric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen procesos enzimáticos y químicos para la preparacion de ciertos derivados de ácido 3-fenil-2-arilalquiltiopropionico que tienen utilidad en el tratamiento de afecciones clínicas que incluyen trastornos lipídicos (dislipidemias), asociados o no con resistencia a insulina, y otras manifestaciones del síndrome metabolico; y además, ciertos nuevos intermediarios utilizados en estos procesos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0427524.4A GB0427524D0 (en) | 2004-12-16 | 2004-12-16 | Chemical process |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052054A1 true AR052054A1 (es) | 2007-02-28 |
Family
ID=34090119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105310A AR052054A1 (es) | 2004-12-16 | 2005-12-16 | Procesos para la preparacion de derivados del acido 3-fenil-2-arilalquilpropionico |
Country Status (17)
Country | Link |
---|---|
US (1) | US7803586B2 (es) |
EP (1) | EP1828394A2 (es) |
JP (1) | JP2008523797A (es) |
KR (1) | KR20070094908A (es) |
CN (1) | CN101080495A (es) |
AR (1) | AR052054A1 (es) |
AU (1) | AU2005315454A1 (es) |
BR (1) | BRPI0518948A2 (es) |
CA (1) | CA2588591A1 (es) |
GB (1) | GB0427524D0 (es) |
IL (1) | IL183524A0 (es) |
MX (1) | MX2007007219A (es) |
NO (1) | NO20072633L (es) |
SA (1) | SA05260405A (es) |
TW (1) | TW200636071A (es) |
UY (1) | UY29271A1 (es) |
WO (1) | WO2006064213A2 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001011072A1 (en) | 1999-08-05 | 2001-02-15 | Novo Nordisk A/S | Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids |
JP2003506065A (ja) * | 1999-08-05 | 2003-02-18 | ノボ ノルディスク アクティーゼルスカブ | 置換された3−フェニル−プロパン酸エステル及び置換された3−フェニル−プロパン酸の調製の方法 |
SE0104333D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
GB0314131D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314075D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314130D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314260D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2004
- 2004-12-16 GB GBGB0427524.4A patent/GB0427524D0/en not_active Ceased
-
2005
- 2005-12-14 BR BRPI0518948-9A patent/BRPI0518948A2/pt not_active Application Discontinuation
- 2005-12-14 EP EP05818266A patent/EP1828394A2/en not_active Withdrawn
- 2005-12-14 SA SA05260405A patent/SA05260405A/ar unknown
- 2005-12-14 CN CNA200580043506XA patent/CN101080495A/zh active Pending
- 2005-12-14 CA CA002588591A patent/CA2588591A1/en not_active Abandoned
- 2005-12-14 JP JP2007546171A patent/JP2008523797A/ja active Pending
- 2005-12-14 AU AU2005315454A patent/AU2005315454A1/en not_active Abandoned
- 2005-12-14 MX MX2007007219A patent/MX2007007219A/es not_active Application Discontinuation
- 2005-12-14 KR KR1020077015115A patent/KR20070094908A/ko not_active Application Discontinuation
- 2005-12-14 WO PCT/GB2005/004800 patent/WO2006064213A2/en active Application Filing
- 2005-12-14 US US11/793,134 patent/US7803586B2/en not_active Expired - Fee Related
- 2005-12-16 AR ARP050105310A patent/AR052054A1/es not_active Application Discontinuation
- 2005-12-16 TW TW094144603A patent/TW200636071A/zh unknown
- 2005-12-20 UY UY29271A patent/UY29271A1/es not_active Application Discontinuation
-
2007
- 2007-05-24 NO NO20072633A patent/NO20072633L/no not_active Application Discontinuation
- 2007-05-29 IL IL183524A patent/IL183524A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101080495A (zh) | 2007-11-28 |
MX2007007219A (es) | 2007-08-14 |
GB0427524D0 (en) | 2005-01-19 |
UY29271A1 (es) | 2006-07-31 |
US7803586B2 (en) | 2010-09-28 |
WO2006064213A3 (en) | 2006-08-24 |
JP2008523797A (ja) | 2008-07-10 |
SA05260405A (ar) | 2005-12-03 |
KR20070094908A (ko) | 2007-09-27 |
US20080115247A1 (en) | 2008-05-15 |
TW200636071A (en) | 2006-10-16 |
BRPI0518948A2 (pt) | 2008-12-16 |
AU2005315454A1 (en) | 2006-06-22 |
CA2588591A1 (en) | 2006-06-22 |
EP1828394A2 (en) | 2007-09-05 |
WO2006064213A2 (en) | 2006-06-22 |
IL183524A0 (en) | 2007-09-20 |
NO20072633L (no) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000393A1 (es) | Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. | |
CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
CL2017000498A1 (es) | Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013) | |
BRPI0703700A (pt) | nanopartìculas contendo prata com estabilizador de substituição | |
BRPI0514474A (pt) | multiparticulados | |
WO2010049678A3 (en) | Treatment of energy utilization diseases | |
EA201101189A1 (ru) | Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии | |
BRPI0817811A2 (pt) | Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas. | |
ES2488407T3 (es) | Preparación farmacéutica que contiene lipasa de origen bacteriano | |
UY30931A1 (es) | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso | |
CL2011000301A1 (es) | Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer. | |
BRPI1005683A2 (pt) | processo livre de células in vitro de produção de um ácido desoxirribonucleio (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento | |
UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
CY1110860T1 (el) | Αναστροφη μεταγραφαση τελομερασης πτηνου | |
WO2008057930A3 (en) | Methods of treating neuropathic pain with retinoic acid receptor agonists | |
BRPI0512624A (pt) | compostos heteroarila e fenilsulfamoìla substituìdos | |
WO2006073890A3 (en) | Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis | |
MX2015013939A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
BR112014027283A2 (pt) | variantes de enzima aprimoradas | |
MX2007011493A (es) | Modalidades antiinflamatorias. | |
MX2014008521A (es) | Combinacion de beta-hidroxi-beta-metil-butirato, arginina y glutamina, para usarse en el tratamiento de ulceras diabeticas. | |
BR112013009660A2 (pt) | proteína de fusão com fator de atividade ix | |
BR112014029721A2 (pt) | sistema de adaptação de palhetas | |
CR11368A (es) | Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida | |
BRPI0700133A (pt) | composição farmacêutica compreendendo tramadol e cetoprofeno em combinação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |